Bio-Techne Corp - TECH STOCK NEWS

Bio-Techne (NASDAQ: TECH) has announced the release of GMP Transposase mRNA for the TcBuster™ non-viral genome engineering system, aimed at supporting immune cell- and stem cell-based therapy development and manufacturing. The system offers significant advantages over traditional lentivirus-based engineering methods, featuring a hyperactive enzyme capable of delivering multiple genes simultaneously while maintaining high editing efficiency.

The TcBuster system eliminates the need for viral clearance methods, reducing time to market and costs for cell therapy developers. It's compatible with various cell types, including immune cells and stem cells, and can be used for applications like autologous CAR-T, TCR manufacturing, allogeneic NK therapies, and engineering bioprocessing cell lines. Bio-Techne provides both RUO & GMP grade reagents with closed-system manufacturing options.

Bio-Techne (NASDAQ: TECH) has announced a quarterly dividend of $0.08 per share for the quarter ended December 31, 2024. The dividend will be paid on February 28, 2025, to shareholders of record as of February 17, 2025.

The company, a global life sciences organization providing innovative tools and bioactive reagents for research and clinical diagnostics, reported net sales of approximately $1.2 billion in fiscal 2024. Bio-Techne employs around 3,100 people worldwide and maintains a portfolio of thousands of products supporting scientific investigations, biological processes research, drug discovery, and clinical testing.

Bio-Techne (NASDAQ: TECH) reported strong Q2 FY2025 financial results with 9% organic revenue growth to $297.0 million. The company's GAAP EPS increased to $0.22 from $0.17 year-over-year, while adjusted EPS rose to $0.42 from $0.40.

The Protein Sciences segment achieved 8% organic growth (7% reported) to $211.6 million, driven by improving biopharma end-market conditions and momentum in cell and gene therapy workflow solutions. The segment's operating margin improved to 41.2% from 40.3%.

The Diagnostics and Spatial Biology segment demonstrated strong performance with 12% organic growth to $84.1 million, though operating margin decreased to 3.9% from 6.0% due to re-instatement of incentive compensation accruals.

Overall adjusted operating margin remained stable at 30.1%, with volume leverage offsetting compensation accrual impacts.

Bio-Techne (NASDAQ: TECH) has appointed Dr. Amy E. Herr to its Board of Directors, effective February 1, 2025. Dr. Herr, who will serve on the Board's Science & Technology Committee, is currently a Chancellor's Professor of Bioengineering at UC Berkeley and Vice President of the Chan Zuckerberg Biohub Network.

Dr. Herr brings significant experience in bioengineering and leadership roles, including serving as Founding Executive Director of UC Berkeley's Bakar BioEnginuity Hub and on the National Advisory Council for Biomedical Imaging and Bioengineering. Notably, she was a co-founder of Zephyrus Biosciences, which Bio-Techne acquired in 2016.

This appointment completes a two-year board succession process, with Dr. Herr succeeding Dr. Roeland Nusse, who will retire later in 2025. The company's leadership highlighted her deep biological and engineering expertise as particularly valuable for Bio-Techne's strategic direction and growth in proteomic analytical instruments.

Bio-Techne (NASDAQ: TECH) has announced it will host a conference call and webcast on February 5, 2025, at 8:00 a.m. CST to discuss its second quarter fiscal 2025 financial results. Participants can join via phone by dialing 1-877-407-9208 (domestic) or 1-201-493-6784 (international) using Conference ID 13751305. The event will also be accessible through a webcast on the company's investor relations website.

For those unable to attend live, a recorded rebroadcast will be available from 11:00 a.m. CST on February 5 until 11:00 p.m. CST on March 5, 2025. The replay can be accessed by dialing 1-844-512-2921 (domestic) or 1-412-317-6671 (international).

ScaleReady has awarded a $300,000 G-Rex® Grant to BrainChild Bio to support the development of BCB-276, an autologous CAR-T therapy for treating diffuse intrinsic pontine glioma (DIPG), an incurable pediatric brain tumor. The grant is part of ScaleReady's $20M initiative to advance cell and gene-modified cell therapy development.

BrainChild Bio plans to advance BCB-276 into a multi-center Phase 2 pivotal clinical trial in 2025. The grant will help optimize their G-Rex based CAR-T cell manufacturing process, offering process simplicity, consistency, and flexibility. Additionally, BrainChild Bio will have the option to evaluate CellReady's standardized 7-day CAR-T cell process, which uses closed system G-Rex bioreactors and Bio-Techne's ProPak GMP cytokines.

Bio-Techne (NASDAQ: TECH) has announced the launch of new AI-engineered designer proteins through its R&D Systems brand. The expanded portfolio includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available in both RUO and GMP formats), and three Wnt/RSPO Agonist proteins.

These innovative proteins are specifically engineered using advanced AI-based design platforms and protein evolutionary workflows to enhance cellular therapy processes and research applications. The products feature improved functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability, leveraging generative AI trained on nearly five decades of proteomic leadership.

The new proteins are designed to address critical needs in cell culture performance and optimization, particularly in cellular therapy applications, stem cell research, organoid development, and regenerative medicine.

Bio-Techne (NASDAQ: TECH) announced its participation at Phacilitate's Advanced Therapies Week, scheduled for January 20-23, 2025, in Dallas, Texas. The company will showcase its new ProPak™ GMP cytokines and cell and gene therapy solutions at booth 517.

Key highlights include the integration of ProPak liquid GMP cytokines with Wilson Wolf's G-Rex® bioreactor through ScaleReady, offering a closed process solution for T cell manufacturing. The company will also display the Ella™ automated ELISA platform and Simple Plex™ assays for QC release testing.

Dr. David Hermanson, Principal Scientist, will deliver a breakout session on closed system manufacturing on January 21 and host a product demonstration on January 22, focusing on ProPak cytokines integration in T cell manufacturing workflows. Will Geist, President of Bio-Techne's Protein Sciences Segment, emphasized the company's commitment to efficient manufacturing of cell and gene-modified cell therapies.

ScaleReady has awarded a $125,000 G-Rex Grant to Seattle Children's Therapeutics, a division of Seattle Children's Research Institute. The grant will support the integration of advanced technologies into their CAR-T cell platform, which has already utilized G-Rex bioreactors to manufacture cell therapy products for hundreds of clinical trial participants.

As part of the grant, Seattle Children's Therapeutics will explore fully closed G-Rex bioreactors and Bio-Techne's GMP-grade cytokines to optimize manufacturing for future trials. They will also receive early access to G-Rex product development and participate in evaluating new devices, including cell separation technology that isolates T-cells without expensive instrumentation.

This grant is part of ScaleReady's larger $20M initiative to advance cell and gene-modified cell therapy development and manufacturing, with individual grants worth up to $300,000.